
What you need to know about the cancer-fighting HPV vaccine
Every year, there are an estimated 48,000 new cases of cancers associated with the human papillomavirus, or HPV, in the United States, according to the US Centers for Disease Control and Prevention. But in the case of HPV, there actually is a vaccine.
Yet public awareness remains low. Over one-third of American adults are unaware of HPV or the HPV vaccine, according to a new research letter published Thursday in the journal JAMA Oncology. In some states, the numbers are significantly higher.
That's why people need to know about HPV, the cancers linked to the virus, and the effectiveness of the HPV vaccine.
To help with these questions, I spoke with CNN wellness expert Dr. Leana Wen. Wen is an emergency physician and adjunct associate professor at George Washington University. She previously was Baltimore's health commissioner, and she is the mother of two young children.
CNN: What is HPV, and what cancers is it linked to?
Dr. Leana Wen: HPV is a virus that can infect humans. There are over 100 types of HPV. Most HPV infections aren't linked to cancer, but some are. The specific types of cancers associated with HPV infection are cervical cancer, cancers of the vagina, vulva, penis and anus. Some oral and throat cancers are also associated with HPV infection.
Of the cancers linked to HPV, cervical cancer is the most common. Each year in the US, there are about 13,000 new cases of cervical cancer. About 4,000 American women die of this cancer annually. However, as referenced in the new report, it's not just cervical cancer — there are as many as 48,000 new cancer diagnoses linked annually to HPV. It's important for people to understand the association between HPV and cervical cancer as well as the link to other cancer types, including the link to oropharyngeal cancers.
CNN: Do people know if they have HPV — do they have symptoms at the time?
Wen: Some types of HPV cause warts. These tend to be what's called low-risk HPV, meaning HPV that is not linked with cancer. Infections with high-risk HPV do not cause symptoms at the time of infection; symptoms can develop later when precancerous and cancerous cells develop.
According to the National Cancer Institute, HPV infection is very common — so common that nearly all sexually active people become infected with HPV within a few years of becoming sexually active. As much as half of HPV infections involve high-risk HPV.
Most HPV infections are cleared by the body and do not result in cancer. However, some high-risk infections can persist. Over the course of many years, it can lead to the development of precancerous and then cancerous cells.
CNN: How is HPV spread?
Wen: The most common way for HPV to spread is through sexual intercourse. The virus can also spread during close skin-to-skin contact during intercourse.
It's crucial to understand just how widespread HPV is and how high-risk HPV is spread by asymptomatic people. Condoms can lower the risk of spreading HPV, but because HPV can infect areas that condoms don't cover, they don't fully protect against HPV. This is why vaccination is so important, to protect against HPV-causing cancers down the line.
CNN: How effective is the HPV vaccine?
Wen: The HPV vaccines have very high efficacy — close to 100% — for the prevention of cervical cancer in women, according to the CDC. The vaccines have also been found to have very high efficacy in men who have sex with men in preventing anal cancer. The vaccines also reduce the likelihood of developing genital warts.
CNN: When is the vaccine recommended to be given?
Wen: The CDC recommends that preteens receive the first dose of the vaccine at age 11 or 12, though it can be given as early as age 9. For most people 9 through 14, a two-dose series is recommended, with the second shot given six to 12 months after the first. A three-dose series is recommended for people who begin vaccination at ages 15 through 45 and for immunocompromised individuals. The second shot is given one to two months after the first and the third about five months later.
CNN: I have heard some parents say that they don't want their children to get the shot because it may encourage them to have sex earlier. How do doctors and public health experts respond to that concern?
Wen: They would point to the data. A large study published in the journal JAMA Internal Medicine compared over 21,000 vaccinated girls with nearly 186,000 unvaccinated peers and found 'no evidence of increased unsafe sexual behavior.' Other studies have found no association between HPV vaccination status and age of first sexual encounter or number of sexual partners.
Because high-risk HPV is so widespread, protecting against the cancers it can cause is essential. We are fortunate to have a vaccine that is so effective. Giving the vaccine is not about encouraging a particular behavior, but about giving protection in case someone becomes exposed to a virus someday.
CNN: What is your takeaway from this latest report?
Wen: Awareness of HPV and the HPV vaccine remains dangerously low among the general public. In seven states, more than 40% of adults were not aware of HPV; in 13 states, more than 40% were unaware of the vaccine. In 45 states and Washington, DC, more than 60% did not know that HPV could cause oral cancers.
The authors concluded that 'there is a critical need to enhance HPV awareness among adolescents, young adults, parents or caregivers, and pediatric and adult health care professionals.' I agree.
Get inspired by a weekly roundup on living well, made simple. Sign up for CNN's Life, But Better newsletter for information and tools designed to improve your well-being.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNN
an hour ago
- CNN
US patients can now get Ozempic for half price if they can pay cash
Novo Nordisk announced Monday that US patients can now get a month's supply of Ozempic, the blockbuster diabetes drug, for $499, for those who pay for medications on their own and don't go through insurance. The move comes as President Donald Trump is pressuring drugmakers to lower drug costs, which have long been a major health care headache for Americans. He and lawmakers have called out popular but pricey GLP-1 drugs, which are used for diabetes and weight loss, noting they are much more expensive in the United States than in other countries. Trump has also been pushing pharmaceutical manufacturers to provide medications directly to consumers at a lower price, cutting out insurers and other players. Novo Nordisk is making Ozempic, which carries a list price of just under $1,000 per month, available at its NovoCare Pharmacy, which ships medications directly to cash-paying consumers. The drugmaker earlier this year launched the direct-to-consumer pharmacy, offering Wegovy, its in-demand weight loss drug, for $499 a month. Rival Eli Lilly has also slashed the price of its GLP-1 weight loss drug, Zepbound, for self-pay patients. The discounted Ozempic price is also available on other platforms, including Novo Nordisk's website and through a partnership with GoodRx, which offers discounts on prescriptions at many pharmacies. The offer is open to eligible patients with an Ozempic prescription, the drugmaker said. Insurers are more likely to cover Ozempic for those with diabetes than they are Wegovy, and Novo Nordisk offers discounts for those with coverage. However, Novo Nordisk is looking to broaden Ozempic's availability even further. 'While Ozempic is well covered in the US, let's not forget that there are some patients who pay out-of-pocket for this vital medicine,' Dave Moore, executive vice president, of Novo Nordisk's US operations, said in a statement. 'We believe that if even a single patient feels the need to turn to potentially unsafe and unapproved knockoff alternatives, that's one too many.' The company noted in its second-quarter earnings call this month that compounding pharmacies, which are allowed to make versions of medications approved by the US Food and Drug Administration when drugs are in shortage, have affected the sales of its GLP-1 medications. The FDA removed Novo Nordisk's semaglutide-based drugs, Ozempic and Wegovy, along with Eli Lilly's tirzepatide-based drugs, Zepbound and Mounjaro, from the shortage list. Novo Nordisk, however, said compounded versions continue to be sold.


CNN
an hour ago
- CNN
US patients can now get Ozempic for half price if they can pay cash
Prescription drugs Food & healthFacebookTweetLink Follow Novo Nordisk announced Monday that US patients can now get a month's supply of Ozempic, the blockbuster diabetes drug, for $499, for those who pay for medications on their own and don't go through insurance. The move comes as President Donald Trump is pressuring drugmakers to lower drug costs, which have long been a major health care headache for Americans. He and lawmakers have called out popular but pricey GLP-1 drugs, which are used for diabetes and weight loss, noting they are much more expensive in the United States than in other countries. Trump has also been pushing pharmaceutical manufacturers to provide medications directly to consumers at a lower price, cutting out insurers and other players. Novo Nordisk is making Ozempic, which carries a list price of just under $1,000 per month, available at its NovoCare Pharmacy, which ships medications directly to cash-paying consumers. The drugmaker earlier this year launched the direct-to-consumer pharmacy, offering Wegovy, its in-demand weight loss drug, for $499 a month. Rival Eli Lilly has also slashed the price of its GLP-1 weight loss drug, Zepbound, for self-pay patients. The discounted Ozempic price is also available on other platforms, including Novo Nordisk's website and through a partnership with GoodRx, which offers discounts on prescriptions at many pharmacies. The offer is open to eligible patients with an Ozempic prescription, the drugmaker said. Insurers are more likely to cover Ozempic for those with diabetes than they are Wegovy, and Novo Nordisk offers discounts for those with coverage. However, Novo Nordisk is looking to broaden Ozempic's availability even further. 'While Ozempic is well covered in the US, let's not forget that there are some patients who pay out-of-pocket for this vital medicine,' Dave Moore, executive vice president, of Novo Nordisk's US operations, said in a statement. 'We believe that if even a single patient feels the need to turn to potentially unsafe and unapproved knockoff alternatives, that's one too many.' The company noted in its second-quarter earnings call this month that compounding pharmacies, which are allowed to make versions of medications approved by the US Food and Drug Administration when drugs are in shortage, have affected the sales of its GLP-1 medications. The FDA removed Novo Nordisk's semaglutide-based drugs, Ozempic and Wegovy, along with Eli Lilly's tirzepatide-based drugs, Zepbound and Mounjaro, from the shortage list. Novo Nordisk, however, said compounded versions continue to be sold.


Gizmodo
2 hours ago
- Gizmodo
What Seemed Like a Pregnancy Was Actually Something Far More Dangerous
A woman's supposed pregnancy turned out to be something much stranger. In a recent report from her doctors, they detail how the woman had developed an incredibly rare form of ovarian cancer that mimicked the symptoms of pregnancy, even causing a positive pregnancy test. Doctors in India described the case of mistaken identity earlier this July in the journal Oncoscience. After first suspecting the woman had an ectopic pregnancy, the doctors instead discovered a large and rare type of tumor in her right ovary. Thankfully, the cancer was removed before it spread elsewhere, and the woman seems to have responded well to treatment. According to the report, the 36-year-old woman visited doctors three months into having intermittent bouts of heavy menstrual bleeding. She tested positive for a pregnancy on a urine test, and when doctors performed a physical examination, they felt a solid mass along her abdomen consistent with having a 20-week-old fetus. An initial ultrasound appeared to show that the woman was experiencing an ectopic pregnancy, a condition where the embryo forms outside of the uterus, usually in the fallopian tube (ectopic pregnancies are inherently non-viable). After conducting more extensive imaging, they found that she actually had cancer in her right ovary, most likely a choriocarcinoma. Choriocarcinomas are tumors mainly formed from the cells that become the placenta during a pregnancy. It's an especially dangerous cancer since the tumors tend to grow quickly and spread to other parts of the body. The woman's doctors soon performed surgery to assess the progression of her cancer and to treat it if possible. They successfully removed the tumor, along with the woman's uterus, ovaries, and surrounding lymph nodes. Though relatively large, the tumor was still in an early stage of development and hadn't metastasized. When the doctors looked closer, though, they found her cancer was even weirder than first thought. Choriocarcinomas are usually gestational, meaning they're linked to pregnancy; oftentimes, the tumor will even arise from an abnormal and non-viable pregnancy. But the woman's cancer was a non-gestational ovarian choriocarcinoma (NGOC), which only accounts for 0.6% of all reported ovarian germ cell tumors (a germ cell being the actual egg). What's more, the cancer was a pure NGOC, an 'exceedingly rare' subtype made completely out of germ cells and not any other kinds of tissues. An image of the woman's tumor, as well as her uterus and a benign ovarian cyst, can be seen here, but be warned, it's not for the faint of heart. While these cancers aren't tied to pregnancy, they do cause the body to produce high levels of the hormone human chorionic gonadotropin (hCG). Women also produce high levels of hCG during pregnancy, and some tests detect pregnancy through measuring hCG, explaining the woman's positive result. 'NGOC is a rare, distinct, and highly aggressive tumor that predominantly affects young, reproductive-aged women,' the authors wrote. Fortunately, in this case, the cancer appears to have been caught early enough in time. Following surgery, the woman was placed on chemotherapy. And her most recent tests showed that her hCG level had returned to normal, indicating a complete treatment response, according to the doctors. She will need to have regular follow-up tests, including CT imaging, to make sure the cancer isn't staging an unwelcome comeback.